Aspen’s encouraging Emerging Market growth
Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced interim financial results for the six months
Aspen launches novel ARV Combination: Set to further improve treatment options
Johannesburg: Aspen Pharmacare, South Africa’s leading JSE-listed pharmaceutical company, is pleased to announce the launch of EmdoltenTM, a Dolutegravir-based triple combination anti-retroviral (ARV) treatment option.
Aspen’s participation in the 2018 Investment Conference
Sandton – Aspen welcomes President Ramaphosa’s inaugural Investment Conference, aimed at positioning South Africa as a preferred investment destination and at establishing a more predictable
Aspen supports the World Thrombosis Day campaign
Aspen remains committed to the World Thrombosis Day campaign to raise awareness of thrombosis as an urgent and growing public health problem. PARIS, FRANCE – Aspen
Aspen’s revenue increases to R42.6 billion
Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading global pharmaceutical company, has announced today, in conjunction with the announcement of its
Aspen meets with French Prime Minister Philippe and members of his cabinet
Aspen was one of the few companies invited by French Prime Minister Edward Philippe to attend the Health Industry Strategic Meeting on 9 July 2018
Aspen’s continued commitment to Mandela Day
Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading global pharmaceutical company, is, for the eighth consecutive year, participating in Mandela Day
Realising Joost’s dream for MND care
Through public private partnership the Gauteng Department of Health and Chris Hani Baragwanath Academic Hospital (CHBAH) gave recognition to their Motor Neuron Disease (MND) clinic
Media Enquiries
Shauneen Beukes
Group Communications Consultant
+27 31 580 8600
+27 82 389 8900
sbeukes@aspenpharma.com
